BPC-157 in the US: personal import rules

The short answer is no, not lawfully. BPC-157 is not approved by the US Food and Drug Administration for any use in people, which makes it an unapproved new drug^[1]. Under the Federal Food, Drug, and Cosmetic Act, importing an unapproved new drug for personal use is illegal, with only a few narrow exceptions^[2], and BPC-157 does not fit any of them. That is the legal picture. The practical picture, where research-chemical vendors ship vials to US addresses anyway, is messier, and this article covers both.

What follows is educational and journalistic, not legal or medical advice. If you are weighing a decision that carries legal or health consequences, talk to a US attorney and to a clinician who knows your history. We do not sell BPC-157, we do not recommend vendors, and we do not describe import workarounds.

Table of contents

1. How the US classifies BPC-157. 2. The federal rule on personal drug importation. 3. What the FDA and customs actually screen for. 4. Why the pharmacy route is closed too. 5. The grey-market reality, without endorsement. 6. What this is not. 7. What we do not yet know.

How the US classifies BPC-157

BPC-157 has no FDA approval for any indication. The US Department of Defense's Operation Supplement Safety programme states plainly that BPC-157 is not a dietary ingredient, that it is an unapproved drug, and that it cannot be legally prescribed or sold over the counter^[1]. The US Anti-Doping Agency reaches the same conclusion from the sport side: BPC-157 is not currently approved for use as a human drug and is prohibited under the S0 (unapproved substances) category of the WADA Prohibited List^[5].

That status is not a paperwork quirk. It reflects how little human evidence exists. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine found that only three pilot studies have examined BPC-157 in humans and that large, rigorous trials are absent, concluding the compound should be treated as investigational^[3]. Without an approved application, there is no US-authorised product, no assessed dosing range, and no verified quality standard for anything sold under the BPC-157 name.

The federal rule on personal drug importation

The starting point in US law is restrictive. A Government Accountability Office review of the issue put it directly: under current law, the importation of prescription drugs for personal use is illegal, with few exceptions, and all drugs offered for import must meet the requirements of the Federal Food, Drug, and Cosmetic Act^[2]. The FDA cannot admit drugs that appear unapproved, misbranded, or adulterated for the US market. An unapproved new drug like BPC-157 falls squarely in that first bucket.

There is a limited personal-importation policy, but it is enforcement discretion rather than a right. The FDA may permit a small quantity, generally no more than a 90-day supply, of a drug that is not available domestically and that treats a serious condition for which effective treatment is not available in the US, provided the product is not being commercially promoted to US residents and does not present an unreasonable risk^[6]. BPC-157 does not clear that bar. It is not a treatment for a serious condition with no domestic alternative, it is marketed to US buyers by the vendors who ship it, and its safety in humans is essentially uncharacterised^[3]. The exception exists for a cancer drug unavailable in the US, not for a research-chemical peptide.

What the FDA and customs actually screen for

Imported products regulated by the FDA are inspected at entry by US Customs and Border Protection, and shipments that appear to violate the Act are subject to detention and refusal^[2]. CBP screens parcels at land borders and at the international mail facilities that handle inbound packages^[6]. A lyophilised peptide vial sent from an overseas supplier is exactly the kind of shipment that can be held: it appears to be an unapproved drug, and the burden sits on the importer to prove otherwise.

When a shipment is refused, the product is either exported or destroyed, and the importer has a window (typically 90 days from the refusal notice) to respond^[2]. For an individual bringing in a drug for personal use that is then refused and destroyed, the FDA has generally said it does not pursue recovery of storage and destruction costs^[6]. Enforcement is not uniform. The volume of inbound parcels far exceeds inspection capacity, so many small shipments are never opened. That inconsistency is not permission. A parcel that is screened can be seized without return, and the underlying import remains unlawful whether or not any given package is caught.

Why the pharmacy route is closed too

Some readers assume that if a compounding pharmacy will prepare BPC-157, it must be legal. That assumption no longer holds. USADA notes that the FDA has found no legal basis for compounding pharmacies to use BPC-157 in compounded medications^[5], and OPSS reports that the FDA has warned against compounded drugs containing BPC-157 because of safety concerns and potential contamination^[1].

The turning point came in September 2023, when the FDA flagged seventeen peptides, BPC-157 among them, as presenting a notable safety risk in compounding, citing impurity and active-ingredient characterisation problems^[4]. A US advisory committee is scheduled to revisit BPC-157 and several other peptides at a meeting on 23 and 24 July 2026^[4]. Whatever that committee recommends, it advises on what compounders may prepare; it does not grant marketing approval. BPC-157 remains an unapproved drug until a new-drug application succeeds, which is a separate and far longer process.

The grey-market reality, without endorsement

Despite the legal position, BPC-157 is widely available through non-regulated sources, a point the 2025 review makes explicitly while cautioning against use outside a trial setting^[3]. Vendors sell it as a research chemical labelled 'not for human use'. That label does not legalise anything. It does not change the drug's unapproved status, it does not subject the product to pharmaceutical-grade quality controls, and it does not protect a buyer who is plainly importing for personal use.

The quality problem is the part most buyers underestimate. Because there is no regulated supply, what arrives in a grey-market vial is not verified. Identity, purity, and contamination are unknowns, and independent testing of research-chemical peptides has repeatedly found products that are underdosed, mislabelled, or something other than what the vial claims. We report this as harm reduction for readers who already have a product in hand, not as a nudge to buy one.

What this is not

This article does not cover peptides that hold FDA approval. Prescription drugs with an approved US application follow different import and prescribing rules, and the personal-importation policy functions as designed for genuinely unavailable treatments. BPC-157's situation is categorically different because there is no approved product anywhere to reference. For the cross-country picture, see BPC-157 regulation by country and the United States regulation hub.

It also does not tell you how to start, stop, dose, or source BPC-157, and it does not endorse any vendor. If you are considering BPC-157, that conversation belongs with a clinician who knows your medical history, not with a checkout page.

What we do not yet know

The gap between rule and enforcement is real but poorly documented. CBP and the FDA do not publish a seizure rate for individual peptide shipments, so any estimate of how often a personal-quantity vial is intercepted is an inference, not a measured probability. The human safety and efficacy questions are also still open: with only a handful of small human studies, there is no defensible dosing range and no long-term safety profile^[3].

The regulatory picture may shift after the July 2026 advisory-committee meeting^[4]. A change to what compounders may prepare would not make personal importation of a research-chemical vial lawful, but it would change the substance's visibility and could prompt updated FDA guidance. We will revise this page when there is something concrete to report.

Medical disclaimer: this article is for educational and journalistic purposes only and does not constitute medical advice. BPC-157 is an unapproved drug in the United States. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Regulatory disclaimer: this page reflects our understanding of US regulatory status as of 2026-07-27. Rules change. Verify with the FDA, US Customs and Border Protection, or a qualified US attorney before making any decision. PeptideMethods.com is not a law firm and does not provide legal advice.